Clinical Trial Update: Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the selective progesterone receptor modulator CDB-2914 for uterine fibroids (leiomyoma) has completed, with results posted in 2012. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• CDB-2914 (Ulipristal acetate)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Leiomyoma | Phase 2 | Status: COMPLETED | Results posted: 2012-12-18